Please assess the completion status of the following clinical trial:

Trial Title: IMP321 Plus First-line Paclitaxel in Metastatic Breast Carcinoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with stage IV breast adenocarcinoma, histologically proven by biopsy of the primary tumor and/or a metastasis.~* Female not pregnant (or with negative pregnancy test) or male.~* Fertile patients must use effective contraception during and for 3 months after drug administration.~* 18 years or above.~* ECOG performance status 0-1.~* Expected survival longer than three months.~* Resolution of toxicity of prior therapy to grade \< 2 (except alopecia).~* With or without prior adjuvant or neoadjuvant chemotherapy (authorized).~* With or without hormone therapy in adjuvant and/or the advanced setting (authorized).~* Evidence of measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST).~* Biphosphonate therapy must have started at least 4 weeks prior to first dosing of the study drug.~* Asthma or chronic obstructive pulmonary disease allowed provided daily systemic corticosteroid therapy is not required.~* Total white cell count ≥ 3.109/L.~* Platelet count ≥ 100.109/L.~* Hemoglobin \> 9 g/dL or \> 5.58 mmol/L.~* Serum creatinine \< 160 µmol/L.~* Total bilirubin \< 20 mmol/L, except for familial cholemia (Gilbert's disease).~* Serum ASAT and ALAT \< 3 times the upper limit of normal or \< 5 times upper limit of normal if liver metastases are present.~* Able to give written informed consent and to comply with the protocol.~Exclusion Criteria:~* Prior chemotherapy for metastatic breast adenocarcinoma.~* Disease-free interval \< 12 months from last dose of adjuvant chemotherapy.~* Prior high-dose chemotherapy requiring hematopoietic stem cell rescue.~* Inflammatory carcinoma.~* Systemic chemotherapy, hormone or endocrine therapy given as breast cancer therapy within 30 days prior to first dosing of the study drug.~* Any investigational drug within 30 days prior to first dosing of the study drug.~* Candidate for treatment with trastuzumab or administration of trastuzumab within 30 days prior to first dosing of the study drug.~* Known cerebral or leptomeningeal metastases.~* Pregnancy or breast feeding.~* Serious intercurrent infection within the 30 days prior to first dosing of the study drug.~* Motor or sensory peripheral neuropathy ≥ 2 according to the National Cancer Institute criteria.~* Congestive heart failure.~* Active acute or chronic infection.~* Active autoimmune disease requiring immunosuppressive therapy.~* Known HIV positivity.~* Life threatening illness unrelated to cancer.~* Previous malignancies within the last two years other than breast carcinoma, successfully treated squamous cell carcinoma of the skin or in situ carcinoma of the cervix treated with cone biopsy.~* Previous history of major psychiatric disorder requiring hospitalization or any current psychiatric disorder that would impede the patient's ability to provide informed consent or to comply with the protocol.~* Corticosteroids unless used as substitutive therapy or before each injection of paclitaxel.~* Past history of severe allergic episodes and/or Quincke edema.~* Past or present history of any organic disorder likely to modify absorption, distribution or elimination of the study drug.~* Alcohol or substance abuse disorder.~* Radiotherapy within the 30 days prior to first dosing of the study drug.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): IMP321

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete